Difference between revisions of "Team:SDU CHINA"

 
(77 intermediate revisions by the same user not shown)
Line 7: Line 7:
  
 
<style>
 
<style>
−
.bottom{position:relative}
+
.bottom{position:relative;text-align:center}
−
.bottom .bar{width:100%;height:70px;top:0px;background-color:#f6f6f6;display:absolute;z-index:0;position;fixed}
+
.bottom .bar{width:100%;height:70px;top:0px;background-color:#f6f6f6;display:absolute;z-index:2;position;fixed}
−
.bottom .bg{position:static}
+
.bottom .bg{z-index:-2;display:block}
−
+
.bgg{z-index:-2;display:block;positon:relative}
−
.abstract{margin:0 10% auto 10% ;position:relative;padding-top:50px;}
+
 
−
.abstract .title{position:relative;margin:0 auto auto 0;color:#660;font-family:Arial, Helvetica, sans-serif;font-size:30px}
+
.abstract{margin:5em 20% auto 20%;position:relative}
−
.abstract .content{top:10px;position:relative;letter-spacing:0.5px;font-family:Segoe, "Segoe UI", "DejaVu Sans", "Trebuchet MS", Verdana, "sans-serif";font-size:20px;word-break:break-all}
+
.abstract .title{position:relative;margin:0 auto auto 0;color:#0172b4;font-family:Arial, Helvetica, sans-serif;font-size:30px}
 +
.abstract .content{margin:0 auto;letter-spacing:0.02em;word-spacing:0.2em;font-family:Segoe, "Segoe UI", "DejaVu Sans", "Trebuchet MS", Verdana, "sans-serif";font-size:1.2em;word-wrap: break-word ;position:relative;text-indent:2em;text-align:left}
 +
.video{text-align:center;z-index:2;positon:relative}
 +
.foot{margin:10% auto auto auto}
  
−
.foot{width:100%;height:200px;background:#E9E9E9;position:relative;margin-top:40px;}
 
 
</style>
 
</style>
 
</head>
 
</head>
Line 22: Line 24:
 
<div class="bottom">
 
<div class="bottom">
 
    
 
    
−
 
−
 
 
    
 
    
−
<div class="bg" >
+
<div class="bg" >
−
<img src="https://static.igem.org/mediawiki/2017/4/4c/Bg.jpeg" style="width:100%;height:auto">
+
<img src="https://static.igem.org/mediawiki/2017/4/4c/Bg.jpeg" style="width:100%;height:auto" style="width:100%;height:auto">
 
</div>
 
</div>
  
−
</div>
+
<div class="c"><img src="https://static.igem.org/mediawiki/2017/9/92/Abstract.jpeg" style="width:100%;height:auto"></div>  
  
−
<div class="abstract" >
 
−
    <div class="title"><b>Abstract</b></div>
 
−
    <div class="content"><p>Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death among the world with low overall survival rate. In NSCLC, immunotherapy has been indicated
 
−
      as a potential therapy for treating in situ solid tumor. Previous research has indicated that tumor cells can express programmed death-1 ligand (PD-L1) to diminish T-cell effector functions and
 
−
      therefore to achieve immune escape. In our project, gene edition will be incorporated with immunotherapy to eradicate the immune escape occurred in NSCLC. By constructing plasmid with
 
−
      Crispr-Cas 9 system targeting the gene coding for PD-L1, the expression of PD-L1 will be inhibited to restore immune system supervision. To ensure the biosafety, another plasmid with
 
−
      Crsipr-Cas 9 system to cut off the housekeeping gene of two plasmids will be also constructed to suicide both plasmid when PD-L1 expression was not detectable. Better therapeutic effects of          immunotherapy to conquer the NSCLC are hoped to be achieved.</p></div> 
 
−
</div>
 
−
<br><br><br><br><br>
 
  
−
<div>
+
 
−
  <div class="foot"></div>
+
<div class="video" style="background:url('https://static.igem.org/mediawiki/2017/5/55/Bggg.jpeg');background-size:100%;padding-top:12em;height:480px;background-repeat:none">
 +
<video src="https://static.igem.org/mediawiki/2017/1/10/Video.mp4" width="48%" controls="controls">
 
</div>
 
</div>
  
  
 +
<div class="foot"><img src="https://static.igem.org/mediawiki/2017/0/04/Sponsor.jpeg" style="width:80%;height:auto;margin-top:-5em"></div>
 +
<br><br>
 +
<div class="footest"><img src="https://static.igem.org/mediawiki/2017/c/c0/Foot.jpeg" style="width:100%;height:auto"></div>
 +
 +
</div>
 
</body>
 
</body>
 
</html>
 
</html>

Latest revision as of 05:07, 31 October 2017

SDU_CHINA